OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Cutaneous Leishmaniases
Interventions
DRUG

Miltefosine

Miltefosine will be prescribed by the treating physician for a minimum of 4 weeks. If treatment response is not sufficient, treatment extension could be decided by the treating physician up to 8 weeks

Trial Locations (1)

Unknown

RECRUITING

Africa Leprosy, Tuberculosis, Rehabilitation and Training (ALERT) Hospital, Addis Ababa

All Listed Sponsors
collaborator

Alert Hospital, Ethiopia

OTHER

collaborator

Armauer Hansen Research Institute, Ethiopia

OTHER

collaborator

Uppsala University

OTHER

collaborator

The Netherlands Cancer Institute

OTHER

lead

Institute of Tropical Medicine, Belgium

OTHER